For the quarter ending 2025-09-30, LPCN made $114,574 in revenue. -$3,186,832 in net income. Net profit margin of -2781.46%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenues | 114,574 | 622,849 | 0 | 89,565 |
| Research and development | 2,707,777 | 2,136,769 | 1,585,233 | 1,874,721 |
| General and administrative | 767,837 | 890,433 | 1,045,240 | 1,507,412 |
| Total operating expenses | 3,475,614 | 3,027,202 | 2,630,473 | 3,382,133 |
| Operating loss | -3,361,040 | -2,404,353 | -2,630,473 | -3,292,568 |
| Unrealized loss on warrant liability | - | 0 | 138,081 | -84,430 |
| Interest and investment income | 174,208 | 198,637 | 273,574 | 308,845 |
| Total other income | 174,208 | 198,637 | 411,655 | 224,415 |
| Loss before income tax expense | -3,186,832 | -2,205,716 | -2,218,818 | -3,068,153 |
| Income tax expense | - | 0 | - | 481 |
| Net income (loss) | - | - | -2,218,818 | -3,068,634 |
| Net loss attributable to common shareholders | -3,186,832 | -2,205,716 | -2,218,818 | -3,068,634 |
| Basic loss per share attributable to common stock | -0.59 | -0.41 | -0.41 | -0.57 |
| Diluted loss per share attributable to common stock | -0.59 | -0.41 | -0.44 | -0.56 |
| Weighted average common shares outstanding, basic | 5,413,149 | 5,351,957 | 5,347,940 | 5,343,922 |
| Weighted average common shares outstanding, diluted | 5,413,149 | 5,351,957 | 5,347,940 | 5,343,922 |
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)